Harbin Pharmaceutical Group Co., Ltd. (600664)

Harbin Pharmaceutical Group Co., Ltd. (600664)

Harbin Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Harbin Pharmaceutical Group") is a Sino foreign joint venture. Harbin state owned Assets Management Commission holds 38.25%, CITIC Capital Iceland Investment Co., Ltd. holds 19.1%, Huaping Iceland Investment Co., Ltd. holds 18.7%, Harbin state owned enterprise restructuring Management Consulting Co., Ltd. holds 8.5%, Chongqing Harper equity investment fund partnership (limited partnership) holds 10%, Tianjin heimachqi Aviation Investment Management Co., Ltd. holds 5%, Heilongjiang CITIC Capital pharmaceutical industry equity investment partnership (limited partnership) holds 0.425%. It owns the shares of Harbin pharmaceutical, and the people are listed in two listed companies (as of June 30, 2019, Harbin Pharmaceutical Group holds 46.49% of the shares of Harbin Pharmaceutical and 74.82% of the shares of the people's company). Its shares of Harbin Pharmaceutical Co., Ltd. invested $300million in september2018 to subscribe for convertible preferred shares issued by GNC, a health care product of the United States. After the conversion, it will hold gnc40.1% of the shares and become its single largest shareholder.

The group has 11 industrial enterprises, including Harbin Pharmaceutical General Plant, Harbin medicine Sanjing, Harbin medicine six factories, Harbin medicine No.2 factory, Harbin medicine world hall, Harbin medicine biology, Harbin medicine three essence four factories, Harbin medicine Sanjing Mingshui, Harbin medicine three essence thousand cranes, Harbin medicine three essence children, Harbin medicine vaccine and other 11 industrial enterprises, and 2 commercial circulation enterprises and 1 Pharmaceutical Research Institute of Harbin Pharmaceutical people Tongtai and Harbin Pharmaceutical Marketing Co., Ltd.

The group mainly covers six business segments, including antibiotics, over-the-counter drugs and health products, traditional and modern Chinese medicine, biomedical, animal vaccine and pharmaceutical business. Harbin Pharmaceutical Co., Ltd. has 1816 drug approvals and 74 health food approvals. The leading products include calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsule, Shuanghuanglian oral liquid, qianliedil injection, paediatrin Huang Nanmin granule, lacidipine tablets, ceftrian hydrochloride, ibuprofen granules, xingaizhonggai high calcium tablets, etc. By the end of 2018, it has the production capacity of 2200 tons of API, 98million chemical injection, 180million traditional Chinese medicine injections, 2 billion oral liquid, 12 billion tablets, 13.1 billion capsules and 1.2 billion bags of chemical granules.

In 2018, the group has 8 varieties with sales revenue of more than RMB 100 million. It has five famous Chinese trademarks and one old Chinese brand of "Yitang" of "Harbin medicine", "Sanjing", "gaizhonggai", "Baotong" and "Shiyitang". After evaluation, the brand value of "Harbin medicine" alone reached 23.829 billion yuan. In recent years, the group has been awarded the honors of "top 100 pharmaceutical industry enterprises in China", "the most socially responsible enterprise of Chinese medicine", "the top ten leading brand enterprises of Chinese medicine", "the award of quality management of Chinese medicine" and "quality award of Heilongjiang provincial government".

The people of the listed company are engaged in wholesale and retail business of medicine with Thailand, covering more than 10000 product regulations including Chinese traditional medicine, Chinese herbal medicine pieces, chemical pharmaceutical preparations, antibiotics, biological products, biochemical drugs, medical devices and health products. There are 314 people's Tongtai pharmaceutical chains with an annual turnover of 1.15 billion yuan. Its pharmaceutical wholesale enterprises have cooperated closely with more than 1000 medical institutions, 1900 third terminals and nearly 700 commercial customers in Heilongjiang Province. The market coverage of hospitals above grade 3 is over 95%, and the market coverage of hospitals above grade II is more than 90%. Its logistics distribution center is the first and largest modern pharmaceutical logistics center in Northeast China, with a storage capacity of 400000 boxes and annual throughput of 30billion yuan. According to the statistical analysis report on the operation of drug circulation industry in 2018 issued by the Ministry of Commerce, the revenue of the wholesale business of people Tongtai ranked 27th among the national pharmaceutical wholesale enterprises in 2018, and the total sales of retail business ranked 23rd among the national retail enterprises.

The group also has a new drug R & D base, Harbin Pharmaceutical Group Technology Center, covering an area of 40000 square meters and a building area of 38000 square meters. It has five R & D platforms for biological medicine, chemical raw materials, chemical preparations, health food, quality inspection and analysis, 25 patents authorized for invention, 6 production approvals and 17 clinical approvals in recent 5 years.

As of the end of 2018, the total number of employees in Harbin Pharmaceutical Group was 18618. Among them, 15968 formal employees and 2650 temporary employees. 3245 people with intermediate or above titles, accounting for 20% of the official employees; 4916 people with bachelor degree or above, accounting for 31% of the formal staff, including 11 doctoral students and 398 master's degree.

In 2018, the total assets of Harbin Pharmaceutical Group were RMB 14.365 billion; Fixed assets: 3.563 billion yuan; Net assets: 8.303 billion yuan; The operating income was 11.163 billion yuan; The total profit is 636 million yuan; The net profit is RMB 440million and the profit and tax are 1.311 billion yuan.

>> oil pump jack for sale electrical submersible pump manufacturers